Reverse payment settlements arise when generic companies file a…
Pep up your morning with this vitamin-enriched drink! Fresh …
Updated: Wednesday, 28 Nov 2012, 4:35 PM EST
Published : Wednesday, 28 Nov 2012, 4:35 PM EST
BUFFALO, N.Y. (AP) - A western New York company says it has signed a $4.6 million contract with Russia to develop anti-infection drugs.
Buffalo-based Cleveland BioLabs Inc. says the contract with the Ministry of Industry and Trade of the Russian Federation was issued under the federation's "Pharma 2020" pharmaceutical development initiative.
The contract announced Tuesday focuses on Xenomycins, a family of compounds being developed as potential treatments for infectious diseases. It's being handled through Panacela Labs, a biotechnology startup company that was founded last year as a joint venture between Cleveland BioLabs and a Russian investment company.
Comments WLFI.com is migrating to a more stable commenting system called DISQUS. This system is used by CNN, TIME, FOX News, numerous blogging sites and has over 75 Million registered users. Unfortunately we can't migrate our current user accounts to this new system.
To sign up for a DISQUS account, click the DISQUS button just below and to the right and then click Login.
DISQUS lets you login with several different options, including Facebook, Google, Twitter, Yahoo or OpenID. We expect it to allow more conversation and better moderation. If you have any questions, please feel free to comment below.